

AD_____

GRANT NUMBER DAMD17-96-1-6024

TITLE: Transforming Growth Factor- β Receptors in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Michael Reiss, M.D.

CONTRACTING ORGANIZATION: Yale University School of Medicine
New Haven, Connecticut 06520-8047

REPORT DATE: May 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970711 108

DTIC QUALITY INSPECTED 3

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 1997	3. REPORT TYPE AND DATES COVERED Annual (1 May 96 - 30 Apr 97)	
4. TITLE AND SUBTITLE Transforming Growth Factor- β Receptors in Humans			5. FUNDING NUMBERS DAMD17-96-1-6024	
6. AUTHOR(S) Michael Reiss, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Yale University School of Medicine New Haven, Connecticut 06520-8047			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Breast cancers are refractory to TGF β -mediated growth inhibition. We hypothesize that TGF β -resistance can be caused, in principle, by molecular lesions in any of the genes that encode TGF β signaling proteins, that such lesions are likely to occur during the development or progression of human breast cancer, and that they may impact on prognosis or treatment response. We have focused primarily on the type I (T β R-I) and -II (T β R-II) cell surface receptors for TGF β . This first year of the project, we have generated critical reagents and developed assay systems needed to analyze the structure and function of these two genes in breast cancer specimens: 1. The intron-exon organization of both the T β R-I and -II genes have been resolved. This will allow us to embark on a large scale screening of primary breast carcinoma specimens for the presence of structural alterations of these two genes. 2. We have developed assays using T47D human breast carcinoma cells to test the function of specific T β R-II gene mutants. These will allow us to assess the effects of individual mutations on the ability of TGF β to inhibit cell cycle progression and to induce extracellular matrix-related target genes.				
14. SUBJECT TERMS Breast Cancer; Transforming Growth Factor- β ; receptors			15. NUMBER OF PAGES 10	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

 Where copyrighted material is quoted, permission has been obtained to use such material.

 Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

 X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

 In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

 X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

 X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

 X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

5/3/97

Date

DTC QUALITY INSPECTED 8

TABLE OF CONTENTS

FRONT COVER 1

SF 298 REPORT DOCUMENTATION PAGE 2

FOREWORD 3

TABLE OF CONTENTS..... 4

INTRODUCTION 5

BODY..... 5

 Task 1 6

 Task 2 7

CONCLUSIONS..... 9

PUBLICATIONS 9

REFERENCES..... 9

APPENDICES..... 10

INTRODUCTION

Transforming Growth Factor- β (TGF β) is the most potent known inhibitor of cell cycle progression of normal mammary epithelial cells; in addition, it causes cells to deposit increased amounts of extracellular matrix which affects cell-cell and cell-substrate interactions. In general, advanced breast cancers are refractory to TGF β -mediated growth inhibition, while the TGF β they secrete apparently serves to enhance invasion into surrounding structures and perhaps their metastatic potential. The effects of TGF β on cell cycle progression are transduced by two cell surface receptors, TGF β type I (T β R-I) and -II receptors (T β R-II), and relayed from the membrane to the cell nucleus by three recently discovered members of the MAD family of proteins, Smad2, -3, and -4. It is our working hypothesis that TGF β -resistance can, in principle, be caused by molecular lesions in any of these five genes, that such lesions are likely to occur during the development or progression of human breast cancer, and that they may impact on prognosis or treatment response.

This project addresses three of the fundamental research issues raised by the USAMRMC Breast Cancer Research Program. The first question is whether or not molecular lesions of the genes involved in the TGF β signaling pathway contribute to the origin and/or progression of breast cancer. We expect changes in these genes to be relatively late events, perhaps characteristic of metastatic cancer. Secondly, we propose to determine how molecular lesions in the TGF β receptor and/or Smad genes affect receptor function, and how they might play a role in the development and/or progression of breast cancer. Thirdly, we intend to examine the question whether genetic lesions in TGF β receptor and/or Smad genes are able to predict the outcome of patients with breast cancer. Because the anti-tumor effects of anti-estrogens such as tamoxifen are thought to be mediated by the auto- and paracrine induction of TGF β , we wish to test the hypothesis that resistance of hormone-receptor positive cancers to tamoxifen is the result of inactivation of TGF β pathway genes.

BODY

The Statement of Work in our original proposal included the following tasks/timeline:

Task 1. Screening for mutations in TGF β receptor genes in breast cancer

- a. Identification of genetic alterations of TGF β -receptor genes in invasive breast cancer specimens. - Months 1-24
- b. Identification of genetic alterations of TGF β -receptor gene in sets of pre-invasive, primary invasive and metastatic (lymph node positive) breast cancers in order to determine the stage of tumor development at which these mutations occur. Months 12-36.

Task 2. Determination of the functional consequences of TGF β -receptor mutations

Cloning of TGF β -receptor mutants into mammalian expression vectors and transfection into TGF β -sensitive and -resistant human mammary epithelial cells to determine whether the mutations are dominant or recessive, and correlation of the site of mutations within the molecule with the way they affect the cellular phenotype. - Months 12-36

Task 3. To determine the potential clinical significance of genetic alterations of the T β R-II gene in breast cancer

Test the hypothesis that genetic alterations of TGF β -receptor gene predict for resistance to anti-estrogen therapy in patients with estrogen-receptor positive tumors. Months 36-48.

This report concerns progress achieved on Tasks 1 and 2, which we will describe separately:

Task 1. Screening for mutations in TGF β receptor genes in breast cancer

Our initial studies of genes involved in TGF β signaling focused on the T β R-II gene. Using a chemical mismatch cleavage (CCM) assay, we were the first to identify missense mutations within the T β R-II serine-threonine kinase domain in human head-&-neck cancer cell lines [1]. These findings raised two important questions: (1) Did such structural alterations of the T β R genes also occur in primary tumors (particularly breast cancers) *in vivo*? and (2) How did these mutations in the T β R-II gene affect receptor function?

Before we could embark on a large study of the T β R genes in breast cancer specimens, several stumbling blocks had to be overcome. The first one was the fact that there was no information on the genomic organization of either the T β R-I or -II genes. This type of information is essential for any comprehensive analysis of these genes in cases in which only genomic DNA from primary tissue specimens was available, such as from paraffin-embedded specimens. Furthermore, knowing the intron-exon boundaries would allow us to screen genomic DNA using a simpler and less laborious assay than CCM, based, for example, on single-strand conformation polymorphisms (SSCP). Because only cDNA sequences were available at the time, we were limited to studies of cell lines and/or tissue specimens from which we could extract intact mRNA as template for cDNA synthesis. This represented a serious limitation for primary tumor studies because only a subset of surgically removed primary breast cancers are frozen (~50%), and the quality of extractable mRNA is highly dependent on the rapidity with which the tissue was frozen after surgery. Because we have access to much larger numbers of paraffin-embedded than frozen breast cancer specimens at Yale, we felt that it was important to define the genomic organization of both the human T β R-II and -I genes.

In order to obtain genomic clones that contained the T β R-I gene, a human genomic library cloned into bacterial artificial chromosomes (BAC) [2] was screened using a full-length T β R-I cDNA (ALK-5 [3]) as probe at Genome Systems, Inc. (St. Louis, MO). We obtained three individual BAC clones (BACH-527(A15), -559(G15), -564(C12)) that hybridized with the ALK-5 probe in two sequential screens. In order to confirm that the BAC clones contained T β R-I-specific genomic sequences and to generate a preliminary restriction map, purified BAC DNA was subjected to Southern blot analysis using three different DNA fragments derived from the 5' end, an internal portion and the 3' untranslated region of the T β R-I cDNA, respectively. DNA from two of the three clones (BACH-559 and -564) hybridized strongly with all three ALK-5 probes, even under stringent conditions, indicating that both of these BAC clones encompassed the complete coding sequence as well as the 3' untranslated portion of T β R-I or a related gene. The restriction patterns differed somewhat between clones BACH-559 and -564, suggesting that we might be dealing with two different genes. This was confirmed by PCR analysis. Using two nested sets of oligonucleotide primers specific for T β R-I cDNA sequences and reaction conditions optimized for long-range PCR, we were able to amplify DNA fragments from BACH-559 but not BACH-564. These results indicated that only clone BACH-559 contained the full-length human T β R-I gene sequence.

To determine the location of the intron-exon boundaries within the T β R-I gene, we designed a series of oligonucleotides that matched sequences located at approximately 300 bp intervals along the ALK5 (T β R-I) cDNA, which were then used for direct sequencing of purified BACH-559 DNA. The location of each intron-exon boundary was confirmed by designing a second oligonucleotide primer based on intronic sequences for DNA sequencing in the reverse orientation. As summarized in **Table 1**, the T β R-I gene consists of nine exons, with sizes ranging from 125 to more than 1,000 bp. Exon 1 contains the ATG start codon and extends at least as far upstream as the transcription start site [4]. Most of the extracellular domain of the receptor is encoded by the first two exons. Exon 3 encodes the transmembrane domain, the juxtamembrane

region, as well as the GS-domain. The serine-threonine kinase domain is encoded by exons 4 through 9. Exon 9 encodes the C-terminus of the protein, and extends at least as far as the 3' end of the published ALK5 sequence [3]. Each of the exon-intron junctions follow the GT-AG rule for splice-acceptor and -donor sites. Based on the Southern blot analysis, direct sequencing of BACH-559 DNA, and PCR amplification of individual introns using flanking oligonucleotide primer sets (data not shown), we were able to calculate the molecular sizes of the individual introns (Table 1). We estimate that the human TBR-I gene is approximately 31 kb in length.

Table 1. Organization of the TBR-I Gene

Exon	3' Splice acceptor	5' End of exon	Exon size (bp)	3' End of exon	5' Splice donor	Estimated intron size (bp)
1		TGCCTGGCGG	329	GGGGCGACGG	gtgagcggcg	4,900
2	cttttccag	CGTTACAGTG	246	CCAACTACTG	gtaagtgtga	3,200
3	ccttttcag	TAAAGTCATC	231	TCTGGCTCAG	gtaacataat	4,550
4	ttaccttag	GTTTACCATT	231	GACAATAAAG	gtctgtaaca	4,700
5	tgttttacag	ACAATGGTAC	168	GGTACCCAAG	gtaattctat	2,300
6	gattcttag	GAAAGCCAGC	157	GAACAAAAAG	gtatactttt	1,700
7	tttttttag	GTACATGGCC	125	TCCATTGGTG	gtaaattgct	1,100
8	ctgatacag	GAATTCATGA	131	GAGCTGTGAA	gtgagtattt	1,400
9	tttctgtag	GCCTTGAGAG	≥ 845			

The genomic organization of the segment of the human SKR-2 gene (identical to ActR-IB and ALK-4) that encodes the serine-threonine kinase domain had been reported previously [5]. The intron-exon junctions within the 3' end of the SKR-2/ActR-IB gene match up precisely with those we identified in the human TBR-I gene. Furthermore, there is a high degree of sequence homology between ALK-5 (TBR-I) and other members of the human R-I receptor gene family (ranging from 74% for ActR-IB to 55% for ALK-1) for the region that encodes the juxtamembrane and serine-threonine kinase domains. Thus, it is likely that the region of these genes that encodes the intracellular portion of the respective receptor proteins was derived from a common ancestral gene and that their exon-intron organization is similar. On the other hand, the mouse ActR-IA gene [6] is composed of 10 exons, which only approximately match the locations of the corresponding exons in the human TBR-I and ActR-IB genes, suggesting that this gene has evolved independently of the ActR-IB and TBR-I genes.

Recently two groups of investigators have independently reported the cloning of the human TBR-II gene and its genomic organization [7, 8]. Thus, at this point we have all of the necessary tools to begin screening primary breast carcinoma specimens for structural alterations within the TBR-I and -II genes using an SSCP-based assay. In collaboration with our breast pathologist, Dr. Daryl Carter, we have selected a series of 36 primary stage I and -II breast carcinoma specimens for which both frozen and paraffin-embedded material is available. This panel will allow us to estimate both the frequency of structural alterations of the TBR-I and -II genes in breast cancer, and the levels of mRNA expression of these genes using an RT-PCR-based assay [9].

Task 2. Determination of the functional consequences of TGFβ-receptor mutations

As indicated above, we were the first to identify missense mutants (R537P and E526Q) of the TBR-II gene in the TGFβ-resistant human head-&-neck SCC cell lines A253 and SqCC/Y1 [1]. Because we anticipate that we will encounter mutations in the TBR-I and -II genes in human breast cancers as well, we needed to develop an experimental strategy that would allow us to precisely determine the consequences of individual mutations for receptor function.

In order to specifically determine which properties of the mutant TBR-II receptors could be

attributed to the E526Q and R537P mutations, we introduced the appropriate nucleotide substitutions into a mouse wild type T β R-II cDNA contained within the p122 expression vector by site-directed mutagenesis [10]. p122 was chosen because it consistently gives high levels of expression of T β R-II protein in mammalian cells [10]. Moreover, the amino acid sequence of the mouse T β R-II is 98% homologous with the human sequence overall, with 100% homology within subdomain XI of the serine-threonine kinase domain where both mutations are located [11]. The properties of these mutant T β R-II cDNAs were analyzed by expressing them in the human breast carcinoma cell line T47D. This cell line was selected because it is refractory TGF- β 1 based on the absence of T β R-II mRNA and protein [12], as indicated by the fact that responsiveness to TGF β can be completely restored by the re-introduction of a wild-type T β R-II cDNA [12]. As surrogate markers for the effects of TGF β on cell cycle progression and induction of ECM-associated protein genes we used reporter gene constructs driven by a cyclin A gene promoter (pCAL2) or PAI-1 gene promoter (3TP-Lux), respectively [10, 13].

Transient expression of wild type T β R-II in T47D cells resulted in a greater than 90% reduction in cyclin A promoter activity compared to cells transfected with a control vector, pcDNA3. The repression of the cyclin A promoter occurred independently of the addition of exogenous TGF β 1, presumably because T47D cells release significant amounts of active TGF β 2 into their culture medium [14]. In contrast, cyclin A promoter activity was repressed by only 20% and 40% in cells transfected with the E526Q and R537P receptor mutants, respectively. Thus, both receptor mutants are deficient in their ability to transduce TGF β 's inhibitory effect on cell cycle progression.

Transfection of wild type T β R-II into T47D cells resulted in a 20% increase in PAI-1 gene promoter activity compared to control cells, with an additional 40% increase in response to TGF β 1 treatment. In contrast, no induction of the PAI-1 promoter was observed in cells transfected with either the E526Q or the R537P mutant. Thus, these two mutations also abolish the ability of the T β R-II receptor to transduce the effects of TGF β on ECM-associated genes. Both wild type and mutant T β R-II receptors could be detected in transfected T47D cells by immunoprecipitation: Cells transfected with either wild type or mutant T β R-II cDNAs expressed approximately equal levels of T β R-II protein, whereas no endogenous T β R-II was detectable in control transfectants. Moreover, similar amounts of T β R-I receptor protein were detectable in immunoprecipitates of cells transfected with wild type or mutant T β R-II. These results indicate that phenotypic differences observed between the mutant and wild type T β R-II receptors were not due to differences in levels of protein expression nor to differences in the ability of the mutant receptors to form complexes with endogenous T β R-I.

Interestingly, baseline PAI-1 promoter activity was decreased by 55-60% in cells transfected with either the E526Q or the R537P T β R-II mutant compared to control transfectants. One explanation for this observation is that T47D cells express very low levels of wild type T β R-II, which is sufficient to induce PAI-1 promoter activity, and that both mutants (which are expressed at much higher levels) effectively compete for interaction with T β R-I, resulting in a reduction in PAI-1 expression. On the other hand, several studies have suggested that T β R-II is not required for cells to respond to TGF β with the induction of ECM-associated proteins [15, 16]. If this model is correct, our results suggest that both T β R-II mutants interfere with T β R-I receptor function in a dominant-negative fashion. In order to clarify this issue, cells were co-transfected with wild type and mutant T β R-II cDNAs. Neither cyclin A nor PAI-1 promoter activity was affected by co-transfecting a mutant T β R-II with the wild type cDNA. These results indicate that neither mutant is a competitive inhibitor of wild type T β R-II function.

In summary, the human breast carcinoma cell line, T47D, is an ideal target cell line to test the function of T β R-II gene mutants. Both missense mutations in the T β R-II gene that we had previously identified in human head-&-neck cancer cells largely abolish the capability of the TGF β receptor system to transduce TGF β 's effects on cell cycle progression as well as induction of

ECM-associated proteins. In addition, our study indicates that these TBR-II mutants inhibit TBR-I function in a dominant-negative fashion.

CONCLUSIONS

1. The intron-exon organization of both the TBR-I and -II genes have been resolved. This allows us to now embark on a large scale screening of primary breast carcinoma specimens for the presence of structural alterations of both genes.
2. We have developed experimental assays using T47D human breast carcinoma cells to test the function of specific TBR-II gene mutants. These assays allow us to assess the effects of individual mutations on the ability of TGF β to inhibit cell cycle progression and to induce extracellular matrix-related target genes.

PUBLICATIONS RESULTING FROM THIS WORK

Reiss, M. ; Barcellos-Hoff, M.H. The role of Transforming Growth Factor- β in breast cancer-A working hypothesis. *Breast Cancer Res. Treatm.* In Press:1997.

REFERENCES

1. Garrigue-Antar, L.; Munoz-Antonia, T.; Antonia, S.J.; Gesmonde, J.; Vellucci, V.F. ; Reiss, M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. *Cancer Res* 55:3982-3987; 1995.
2. Shizuya, H.; Birren, B.; Kim, U.-J.; Mancino, V.; Slepak, T.; Tachiiri, Y. ; Simon, M. Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in *Escherichia coli* using an F-factor-based vector. *Proc. Natl. Acad. Sci. USA* 89:8794-8797; 1992.
3. Franzén, P.; Ten Dijke, P.; Ichijo, H.; Yamashita, H.; Schulz, P.; Heldin, C.-H. ; Miyazono, K. Cloning of a TGF β type I receptor that forms a heterodimeric complex with the TGF β type II receptor. *Cell* 75:681-692; 1993.
4. Bloom, B.B.; Humphries, D.E.; Kuang, P.-P.; Fine, A. ; Goldstein, R.H. Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor- β receptor: regulation by TGF β . *Biochim. Biophys. Acta* 1312:243-248; 1996.
5. Xu, J.; Matsuzaki, K.; McKeehan, K.; Wang, F.; Kan, M. ; McKeehan, W.L. Genomic structure and cloned cDNAs predict that four variants in the kinase domain of serine/threonine kinase receptors arise by alternative splicing and poly(A) addition. *Proc Natl Acad Sci U S A* 91:7957-7961; 1994.
6. Schmitt, J.; Mielke, R. ; Schrewe, H. Genomic organization of a mouse type I activin receptor. *Biochem Biophys Res Commun* 213:211-7; 1995.
7. Lu, S.; Zhang, W.; Akiyama, Y.; Nomizu, T. ; Yuasa, Y. Genomic structure of the transforming growth factor β type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. *Cancer Res.* 56:4595-4598; 1996.
8. Takenoshita, S.; Hagiwara, K.; Nagashima, M.; Gemma, A.; Bennett, W.P. ; Harris, C.C. The genomic structure of the gene encoding the human transforming growth factor β type II receptor (TGF- β). *Genomics* 36:341-344; 1996.
9. Garrigue-Antar, L.; Souza, R.F.; Vellucci, V.F.; Meltzer, S.J. ; Reiss, M. Loss of

transforming growth factor- β type II receptor gene expression in human esophageal cancer. *Lab. Invest.* 75:263-272; 1996.

10. Feng, X.-H.; Filvaroff, E.H. ; Derynck, R. Transforming Growth Factor- β (TGF β)-induced down-regulation of cyclin A expression requires a functional TGF β receptor complex. *J. Biol. Chem.* 270:24237-24245; 1995.

11. Lawler, S.; Candia, A.F.; Ebner, R.; Shum, L.; Lopez, A.R.; Moses, H.L.; Wright, C.V. ; Derynck, R. The murine type II TGF-beta receptor has a coincident embryonic expression and binding preference for TGF-beta 1. *Development* 120:165-175; 1994.

12. Kalkhoven, E.; Roelen, B.A.J.; de Winter, J.P.; Mummery, C.L.; van den Eijnden-van Raaij, A.J.M.; van der Saag, P.T. ; van der Burg, B. Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. *Cell Growth Diff.* 6:1151-1156; 1995.

13. Wrana, J.L.; Attisano, L.; Cárcamo, J.; Zentella, A.; Doody, J.; Laiho, M.; Wang, X.-F. ; Massagué, J. TGF β signals through a heteromeric protein kinase receptor complex. *Cell* 71:1003-1014; 1992.

14. Kalkhoven, E.; Kwakkenbos-Isbrucker, L.; Mummery, C.L.; deLaat, S.W.; van den Eijnden-van Raaij, A.J.M.; van der Saag, P.T. ; van der Burg, B. The role of TGF- β production in growth inhibition of breast tumor cells by progestins. *Int. J. Cancer* 61:80-86; 1995.

15. Geiser, A.G.; Burmester, J.K.; Webbink, R.; Roberts, A.B. ; Sporn, M.B. Inhibition of growth by transforming growth factor- β following fusion of two nonresponsive human carcinoma cell lines. *J. Biol. Chem.* 267:2588-2593; 1992.

16. Sankar, S.; Mahooti-Brooks, N.; Bensen, L.; McCarthy, T.L.; Centrella, M. ; Madri, J.A. Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. *J Clin Invest* 97:1436-46; 1996.

APPENDICES

None